

Pharmacy Prior Approval for Hetlioz and Hetlioz LQ

Beneficiary Information

1. Beneficiary Last Name:	2. First Name:	
3. Beneficiary ID #:	4. Beneficiary Date of Birth:	5. Beneficiary Gender:
Prescriber Information		
6. Prescribing Provider NPI #:		
7. Requester Contact Information	n - Name: Phone #:	Ext.
Drug Information		
8. Drug Name:	9. Strength:	10. Quantity Per 30 Days:
11. Length of Therapy (In days): I	nitial Request: 🗌 up to 30 Days 🗌 60 Days 🗌 90	Days
Re-authorization: 🗌 up to 30 Days 🗌 60 Days 🗌 90 Days 🗌 120 Days 🗌 180 Days		
Clinical Information		
HETLIOZ (complete questions 1-	5 for Helioz)	
1. Is the beneficiary 18 years old		
2. Does the beneficiary have a documented diagnosis of Non-24 sleep-wake disorder? Yes No		
3. The diagnosis of Non-24 sleep-wake disorder is confirmed by meeting ONE of the following conditions:		
Assessment of at least one physiologic circadian phase marker (e.g., measurement of urinary melatonin levels, dim light melatonin onset [as measured in blood or saliva], assessment of core body temperature		
By actigraphy performed for >/= 1 week plus evaluation of sleep logs recorded for >/= 1 month		
4. Is the beneficiary 16 years old or older? Yes No		
5. Does the beneficiary have a diagnosis of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS)?		
HETLIOZ LQ (complete questions	6-7 for Hetlioz LQ)	
6. Is the beneficiary between 3 ye	ears and 15 years of age? 🗆 Yes 🗆 No	
	agnosis of nighttime sleep disturbances in Smith-M	1agenis Syndrome (SMS)?
🗆 Yes 🗆 No		
Hetlioz and Hetlioz LQ: (complet	e questions 8-9)	
8. Has the beneficiary had an insufficient response or intolerance to at least two (2) other medications for sleep? (can be over-the-counter or		
prescription) 🛛 Yes 🗆 No		
9. Is this medication being prescr	ibed by, or is the physician consulting with, a physi	ician who specialized in the treatment of sleep disorders? \Box
Yes 🗆 No		
Re-authorization for Hetlioz and	Heltioz LQ: (complete questions 10-11)	
10. Has the beneficiary used Hetlioz/Hetlioz LQ continuously without gaps in treatment for the initial approval period of three (3) months?		
Yes 🗆 No		
11. As the provider, have you included an objective evaluation of the beneficiary's sleep quality, including documentation		
of an improvement in overall sleep quality while taking Hetlioz/Hetlioz LQ? 🗆 Yes 🗆 No		
**Documentation of the benefici Hetlioz/Hetlioz LQ. **	ary's overall sleep quality improvement must acco	mpany this reauthorization for
Signature of Prescriber:	Dat	e:
	(Prescriber Signature Mandatory)	
I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.		

Fax this form to: (833) 404-2393

Pharmacy PA Call Center: (833) 585-4309

https://www.covermymeds.com/main/prior-authorization-forms/